Hepatitis B vaccine antibody response and the risk of clinical AIDS or death

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Landrum, Michael L ^a,b   Hullsiek, Katherine Huppler ^a,c   O'Connell, Robert J ^d   Chun, Helen M ^e   Ganesan, Anuradha ^a,f   Okulicz, Jason F ^b   Lalani, Tahaniyat ^a   Weintrob, Amy C ^a,f   Crum Cianflone, Nancy F ^e   Agan, Brian K ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS VACCINE; HEPATITIS ANTIBODY; HEPATITIS B VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; DELAYED HYPERSENSITIVITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE STATUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; RISK ASSESSMENT; SKIN TEST; VIRUS LOAD; BIOSYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PATHOLOGY; RISK FACTOR;

HEPATITIS B VIRUS;

ADULT; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS;

EID: 84858731691     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033488     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention (2009) Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 58: 1-94.
2. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 126: 946-954.
3. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, et al. (1996) Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New England Journal of Medicine 334: 426-431.
4. The INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee (2009) Interleukin-2 therapy in patients with HIV infection. New England Journal of Medicine 361: 1548-1559.
5. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, et al. (2006) Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296: 1498-1506.
6. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, et al. (2007) CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nature Immunology 8: 1324-1336.
7. Maas JJ, Roos MT, Keet IP, Mensen EA, Krol A, et al. (1998) In vivo delayed-type hypersensitivity skin test anergy in human immunodeficiency virus type 1 infection is associated with T cell nonresponsiveness in vitro. J Infect Dis 178: 1024-1029.
8. Jones-Lopez EC, Okwera A, Mayanja-Kizza H, Ellner JJ, Mugerwa RD, et al. (2006) Delayed-type hypersensitivity skin test reactivity and survival in HIV-infected patients in Uganda: should anergy be a criterion to start antiretroviral therapy in low-income countries? Am J Trop Med Hyg 74: 154-161.
9. Dolan MJ, Clerici M, Blatt SP, Hendrix CW, Melcher GF, et al. (1995) In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. Journal of Infectious Diseases 172: 79-87.
10. Anastos K, Shi Q, French AL, Levine A, Greenblatt RM, et al. (2004) Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 35: 383-392.
11. Blatt SP, Hendrix CW, Butzin CA, Freeman TM, Ward WW, et al. (1993) Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Annals of Internal Medicine 119: 177-184.
12. Birx DL, Brundage J, Larson K, Engler R, Smith L, et al. (1993) The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 6: 1248-1257.
13. Meroni L, Marchetti G, Gatti N, d'Arminio Monforte A, Galli M, (2003) Delayed-type hypersensitivity skin testing can predict CD4 count increase in HIV patients with poor immunologic response to HAART. J Acquir Immune Defic Syndr 33: 277-278.
14. Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, et al. (2004) Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 39: 609-629.
15. Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, et al. (2010) Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 24: 545-555.
16. Bauer T, Jilg W, (2006) Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 24: 572-577.
17. Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, et al. (1991) The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 173: 531-538.
18. Filion LG, Saginur R, Szczerbak N, (1988) Humoral and cellular immune responses by normal individuals to hepatitis B surface antigen vaccination. J Exp Immunol 71: 405-409.
19. Goncalves L, Albarran B, Salmen S, Borges L, Fields H, et al. (2004) The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 326: 20-28.
20. Valdez H, Smith KY, Landay A, Connick E, Kuritzkes DR, et al. (2000) Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. AIDS 14: 11-21.
21. Loke RH, Murray-Lyon IM, Coleman JC, Evans BA, Zuckerman AJ, (1990) Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis. Journal of Medical Virology 31: 109-111.
22. Chun HM, Fieberg AM, Hullsiek KH, Lifson AR, Crum-Cianflone NF, et al. (2010) The epidemiology of hepatitis B virus infection in a U.S. cohort of HIV-infected individuals during the last 20 years. Clinical Infectious Diseases 50: 426-436.
23. Landrum ML, Fieberg AM, Chun HM, Crum-Cianflone NF, Marconi VC, et al. (2010) The effect of human immunodeficiency virus on hepatits B virus serological status in co-infected adults. PLoS One 5: e8687.
24. Landrum ML, Hullsiek KH, Chun HM, Crum-Cianflone NF, Ganesan A, et al. (2011) The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. American Journal of Epidemiology 173: 84-83.
25. Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, et al. (2009) Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: Another benefit of HAART in those with preserved CD4 count. Vaccine 27: 4731-4738.
26. Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, et al. (2003) Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS 17: 2521-2527.
27. Centers for Disease Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41 Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed Jan 4, 2008.
28. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, et al. (1989) Genetic prediction of nonresponse to hepatitis B vaccine. New England Journal of Medicine 321: 708-712.
29. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, et al. (1986) Nonresponsiveness to hepatitis B vaccine in health care workers: results of revaccination and genetic typings. Annals of Internal Medicine 105: 356-360.
30. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, et al. (2004) HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39: 978-988.
31. Moir S, Fauci AS, (2008) Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 122: 12-19.
32. Moir S, Ogwaro KM, Malaspina A, Vasquez J, Donoghue ET, et al. (2003) Pertubations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. PNAS 100: 6057-6062.
33. Pessoa SD, Miyamoto M, Ono E, Gouvea AFTB, de Moraes-Pinto MI, et al. (2010) Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART. Vaccine 28: 1606-1612.
34. del Mar del Pozo Balado M, Leal M, Lagares GM, Mata RC, Lopez-Cortes LF, et al. (2010) Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. Journal of Infectious Diseases 202: 362-369.
35. Holmes D, Jiang Q, Zhang L, Su L, (2008) Foxp3 and Treg cells in HIV-1 infection and immuno-pathogenesis. Immunology Research 41: 248-266.
36. Yang Z, Wang L, Niu W, Wu Y, Zhang J, et al. (2008) Increased CD4+CD25+FoxP3+ regulatory T cells in the blood of nonresponders after standard hepatitis B surface antigen vaccine immunization. Clinical Immunology 127: 256-266.
37. Appay V, Almeida JR, Sauce D, Autran B, Papagno L, (2007) Accelerated immune senescence and HIV-1 infection. Experimental Gerontology 42: 432-437.
38. Appay V, Rowland-Jones SL, (2002) Premature ageing of the immune system: the cause of AIDS? Trends in Immunology 23.
39. Effros RB, (2007) Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 25: 599-604.
40. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, et al. (2003) Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 17: 2015-2023.
41. Hunt PW, (2007) Role of immune activation in HIV pathogenesis. Current HIV/AIDS Reports 4: 42-47.
42. Effros RB, Dagarag MD, Spaulding CC, Man J, (2005) The role of CD8 T cell replicative senescence in human aging. Immunology Reviews 205: 147-157.
43. Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, et al. (2010) Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. military HIV natural history study. AIDS Research and Therapy 7: 14.